Day: February 22, 2021

In heterogeneous catalysis, the catalyst is in a different phase from the reactants. Recommanded Product: 5291-32-7, At least one of the reactants interacts with the solid surface in a physical process called adsorption in such a way. 5291-32-7, name is APR-246. In an article£¬Which mentioned a new discovery about 5291-32-7

PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and noxa

Targeting p53 by the small-molecule PRIMA-1Met/APR-246 has shown promising preclinical activity in various cancer types.However, the mechanism of PRIMA-1Met-induced apoptosis is not completely understood and its effect on multiple myeloma cells is unknown. In this study, we evaluated antitumor effect of PRIMA-1Met alone or its combination with current antimyeloma agents in multiple myeloma cell lines, patient samples, and a mouse xenograft model. Results of our study showed that PRIMA-1Met decreased the viability of multiple myeloma cells irrespective of p53 status, with limited cytotoxicity toward normal hematopoietic cells. Treatment of multiple myeloma cells with PRIMA-1Met resulted in induction of apoptosis, inhibition of colony formation, and migration. PRIMA-1Met restored wild-type conformation of mutant p53 and induced activation of p73 upregulating Noxa and downregulating Mcl-1 without significant modulation of p53 level. siRNAmediated silencing of p53 showed a little effect on apoptotic response of PRIMA-1Met, whereas knockdown of p73 led to substantial attenuation of apoptotic activity in multiple myeloma cells, indicating that PRIMA-1Met- induced apoptosis is, at least in part, p73-dependent.Importantly, PRIMA-1Met delayed tumor growth and prolonged survival of mice bearing multiple myeloma tumor. Furthermore, combined treatment of PRIMA-1Met with dexamethasone or doxorubicin displayed synergistic effects in both multiple myeloma cell lines and primary multiple myeloma samples. Consistent with our in vitro observations, cotreatment with PRIMA-1Met and dexamethasone resulted in enhanced antitumor activity in vivo. Our study for the first time shows antimyeloma activity of PRIMA-1Met and provides the rationale for its clinical evaluation in patients with multiple myeloma, including the high-risk group with p53 mutation/deletion. Mol Cancer Ther; 12(11); 2331-41.

Recommanded Product: 5291-32-7, Interested yet? Read on for other articles about Recommanded Product: 5291-32-7!

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H174N | ChemSpider

In heterogeneous catalysis, the catalyst is in a different phase from the reactants. HPLC of Formula: C8H16N2, At least one of the reactants interacts with the solid surface in a physical process called adsorption in such a way. 67496-78-0, name is Quinuclidin-4-ylmethanamine. In an article£¬Which mentioned a new discovery about 67496-78-0

CEPHEM DERIVATIVE HAVING CATECHOL GROUP

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof wherein A represents a group represented by one of formulae (i)-(iii); B represents a group represented by formula (v) or (vi); and E represents a substituted or unsubstituted heterocyclic group having a cationic nitrogen atom.

If you are interested in HPLC of Formula: C8H16N2, you can contact me at any time and look forward to more communication. HPLC of Formula: C8H16N2

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H24N | ChemSpider

123536-14-1, Name is (R)-3-Aminoquinuclidine dihydrochloride, belongs to quinuclidine compound, is a common compound. HPLC of Formula: C7H16Cl2N2In an article, once mentioned the new application about 123536-14-1.

PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound of formula (VII)I, or a pharmaceutically acceptable salt or ester thereof, wherein: X is NR7; Y is O or N-(CH2)nR19; n is 1, 2 or 3; m is 1 or 2; R1 and R2 are each independently H, alkyl or cycloalkyl; R4 and R4′ are each independently H or alkyl; or R4 and R4′ together form a spiro cycloalkyl group; R19 is H, alkyl, aryl or a cycloalkyl group; R6 is OR8 or halogen; and R7 and R8 are each independently H or alkyl. Further aspects relate to pharmaceutical compositions comprising said compounds and use therefore in the treatment of proliferative disorders and the like

The proportionality constant is the rate constant for the particular unimolecular reaction. the reaction rate is directly proportional to the concentration of the reactant. I hope my blog about 123536-14-1 is helpful to your research. HPLC of Formula: C7H16Cl2N2

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H108N | ChemSpider

An article , which mentions 123536-14-1, molecular formula is C7H16Cl2N2. The compound – (R)-3-Aminoquinuclidine dihydrochloride played an important role in people’s production and life., Application In Synthesis of (R)-3-Aminoquinuclidine dihydrochloride

Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease

The invention provides compounds of Formula I: 1wherein Azabicyclo is any of: 2These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which alpha7 is known to be involved.

Application In Synthesis of (R)-3-Aminoquinuclidine dihydrochloride, Interested yet? Read on for other articles about Application In Synthesis of (R)-3-Aminoquinuclidine dihydrochloride!

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H99N | ChemSpider

827-61-2, Name is Quinuclidin-3-yl acetate, belongs to quinuclidine compound, is a common compound. Formula: C9H15NO2In an article, once mentioned the new application about 827-61-2.

COMPOSITIONS AND METHODS TO MODULATE MEMORY

Disclosed herein are compositions and methods for modulating memory. In one aspect, the regulation of protein expression of certain proteins related to both long-term and short-term memory is described. In one aspect, modulating the RISC pathway and associated targets is described.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Formula: C9H15NO2. In my other articles, you can also check out more blogs about 827-61-2

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H30N | ChemSpider

Chemistry is the experimental science by definition. We want to make observations to prove hypothesis. For this purpose, we perform experiments in the lab. 123536-14-1, Name is (R)-3-Aminoquinuclidine dihydrochloride,introducing its new discovery., Computed Properties of C7H16Cl2N2

Improved preparation of (R) and (S)-3-aminoquinuclidine dihydrochloride

An improved procedure for the synthesis of either (R) or (S)-3-aminoquinuclidine was developed. Key intermediate imine 2 was made in a one pot process using lithium oxide as the base and molecular sieves.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 123536-14-1

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H146N | ChemSpider

Let¡¯s face it, organic chemistry can seem difficult to learn. Especially from a beginner¡¯s point of view. Like 123536-14-1, Name is (R)-3-Aminoquinuclidine dihydrochloride. In a document type is Article, introducing its new discovery., Product Details of 123536-14-4

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I: 1wherein Azabicyclo is 2These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which alpha7 is known to be involved.

The proportionality constant is the rate constant for the particular unimolecular reaction. the reaction rate is directly proportional to the concentration of the reactant. I hope my blog about 123536-14-1 is helpful to your research. Safety of (R)-3-Aminoquinuclidine dihydrochloride

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H97N | ChemSpider

123536-14-1, Name is (R)-3-Aminoquinuclidine dihydrochloride, belongs to quinuclidine compound, is a common compound. Computed Properties of C7H16Cl2N2In an article, once mentioned the new application about 123536-14-1.

N-AZABICYCLO-AMIDE DERIVATIVES

Compounds of the general formula I wherein A represents: D represents oxygen, or sulfur and R1, R2 and R3 are as defined in the specification, enantiomers thereof, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Computed Properties of C7H16Cl2N2. In my other articles, you can also check out more blogs about 123536-14-1

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H123N | ChemSpider

Children learn through play, and they learn more than adults might expect. Science experiments are a great way to spark their curiosity, get their minds active, and encourage them to do something that doesn¡¯t involve a screen. 123536-14-1, C7H16Cl2N2. A document type is Article, introducing its new discovery., category: quinuclidine

Pharmacological profile of zacopride and new quaternarized fluorobenzamide analogues on mammalian alpha7 nicotinic acetylcholine receptor

Abstract From quaternarization of quinuclidine enantiomers of 2-fluoro benzamide LMA10203 in dichloromethane, the corresponding N-chloromethyl derivatives LMA10227 and LMA10228 were obtained. Here, we compared the agonist action of known zacopride and its 2-fluoro benzamide analogues, LMA10203, LMA10227 and LMA10228 against mammalian homomeric alpha7 nicotinic acetylcholine receptor expressed in Xenopus oocytes. We found that LMA10203 was a partial agonist of alpha7 receptor with a pEC50 value of 4.25 ¡À 0.06 muM whereas LMA10227 and LMA10228 were poorly active on alpha7 homomeric nicotinic receptor. LMA10227 and LMA10228 were identified as antagonists of acetylcholine-induced currents with IC50 values of 28.4 muM and 39.3 muM whereas LMA10203 and zacopride possessed IC50 values of 8.07 muM and 7.04 muM, respectively. Moreover, despite their IC50 values, LMA10227 was the most potent inhibitor of nicotine-induced current amplitudes (65.7 ¡À 2.1% inhibition). LMA10203 and LMA10228 had the same inhibitory effects (26.5 ¡À 7.5% and 33.2 ¡À 4.1%, respectively), whereas zacopride had no significant inhibitory effect (4.37 ¡À 4%) on nicotine-induced responses. Our results revealed different pharmacological properties between the four compounds on acetylcholine and nicotine currents. The mode of action of benzamide compounds may need to be reinterpreted with respect to the potential role of alpha7 receptor.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, category: quinuclidine, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about category: quinuclidine

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H137N | ChemSpider

Reference of 123536-14-1, A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 123536-14-1, Name is (R)-3-Aminoquinuclidine dihydrochloride, molecular formula is C7H16Cl2N2. In a Article£¬once mentioned of 123536-14-1

Directed synthesis of noncentrosymmetric molybdates using composition space analysis

A systematic investigation of the factors governing the reaction product composition, hydrogen bonding, and symmetry was conducted in the MoO 3/3-aminoquinuclidine/H2O system. Composition space analysis was performed through 36 individual reactions under mild hydrothermal conditions using racemic 3-aminoquinuclidine. Single crystals of three new compounds, [C7H16N2][Mo 3O10]¡¤H2O, [C7H 16N2]2[Mo8O26] ¡¤H2O, and [C7H16N2] 2[Mo8O26]¡¤4H2O, were grown. The relative phase stabilities for these products are dependent upon the reactant mole fractions in the initial reaction gel. This phase stability information was used to direct the synthesis of two new noncentrosymmetric compounds, using either (S)-(-)-3-aminoquinuclidine dihydrochloride or (R)-(+)-3-aminoquinuclidine dihydrochloride. [(R)-C7H 16N2]2-[Mo8O26] and [(S)-C7H16N2]2[Mo8O 26] both crystallize in the noncentrosymmetric space group P2 1 (No. 4), which has the polar crystal class 2 (C2). The second-harmonic generation activities were measured on sieved powders. The structure-directing properties of the molybdate components in each compound were determined using bond valence sums. The structures of all five compounds were determined using single-crystal X-ray diffraction.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Reference of 123536-14-1, you can also check out more blogs aboutReference of 123536-14-1

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H155N | ChemSpider